Psilocybin-Assisted Therapy Enters First Lung Cancer Depression Trial

Nearly forty percent of people living with lung cancer experience depression, a figure that far exceeds the rates seen in the general population and that reflects the unique psychological weight carried by this diagnosis. Many patients also contend with anxiety, hopelessness and urgent questions about mortality, often while undergoing demanding treatment regimens. Now, researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, known as the OSUCCC – James, together with the Center for Psychedelic Drug Research and Education in the university’s College of Social Work, have launched a clinical trial to determine whether psilocybin-assisted therapy can reduce depression and emotional distress in patients with lung cancer. The study is the first clinical trial of its kind to focus specifically on people with lung cancer, a population whose mental health needs have long been underserved even as their physical treatment options have expanded.

The trial addresses a pressing and growing gap in cancer care. Advances in targeted therapies, immunotherapies and early detection have allowed many people with advanced lung cancer to live longer than was possible a decade ago, yet the emotional burden of the disease has not diminished. Depression, anxiety and psychological distress can erode daily functioning, strain relationships with family and friends, and undermine a patient’s ability to cope with treatment itself. Despite these well-documented consequences, treatment options for cancer-related depression have changed remarkably little even as cancer care has advanced rapidly. Standard approaches, including antidepressant medications and supportive psychotherapy, help some patients but leave many others without meaningful relief. Investigators hope that a carefully structured psychedelic-assisted intervention may offer a new path forward for those who have not benefited from conventional care.

Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. In the Ohio State study, it is administered in a carefully controlled medical setting, accompanied by extensive counseling and continuous support from trained therapists. This model, often described as psilocybin-assisted therapy, differs fundamentally from recreational or unsupervised use of psychedelic substances. The compound is given as a single supervised dose within a structured therapeutic framework, in which preparation and integration sessions surround the dosing experience. The therapeutic context is considered essential: the goal is not simply to produce a psychedelic experience but to help patients process difficult emotions, confront existential concerns and potentially reframe their relationship to illness and mortality in ways that support lasting psychological benefit.

Alan Davis, PhD, co-principal investigator of the study and director of Ohio State’s Center for Psychedelic Drug Research and Education, emphasized that although evidence has been accumulating for psychedelic therapies in cancer populations generally, lung cancer patients have never been studied specifically. According to Davis, there is growing evidence that psilocybin-assisted therapy may help relieve depression in people with cancer, but no study has focused specifically on patients with lung cancer. He described the trial as the first clinical trial designed to determine whether this approach can address the unique psychological challenges faced by this patient population. That distinction matters because lung cancer carries psychological features that differ from those associated with other malignancies, including a high symptom burden at diagnosis and a stigma that researchers say compounds patients’ distress.

Theodore Wagener, PhD, the study’s other co-principal investigator and director of Ohio State’s Center for Tobacco Research, highlighted how abruptly many lung cancer patients are forced to confront their own mortality. Both Wagener and Davis are scientists with the OSUCCC – James Cancer Control Research Program. Wagener noted that many patients are diagnosed with advanced disease and are forced to confront questions about their future very quickly. He described the range of psychological burdens these patients may carry, including anxiety, existential distress, loss of meaning and concerns about their families. Some patients, he added, also carry guilt tied to the stigma that can be associated with lung cancer, a disease whose strong historical association with smoking can lead patients to feel blame directed at themselves or from others. Researchers say these emotional burdens can degrade quality of life, disrupt daily routines, damage relationships and shape how patients experience their cancer treatment overall.

The treatment protocol being tested in the trial follows a structured, multi-stage model that reflects the current standard in psychedelic clinical research. Participants first complete approximately eight hours of preparation with two trained therapists, a phase designed to establish trust, set expectations and identify the emotional material the patient may wish to explore. They then receive psilocybin during a daylong treatment session conducted in a comfortable clinical setting, with the therapists present throughout to provide support and ensure safety. Following the dosing session, participants take part in additional counseling intended to help them process and integrate the experience. Davis explained that from the moment patients enter the study, they are paired with two therapists who support them throughout the entire process, and that the goal is to help participants feel safe, build trust and make sense of their experiences in ways that may improve their well-being.

Beyond measuring changes in depression and emotional well-being, the researchers are also exploring a biological question: whether psilocybin may affect inflammation. This line of inquiry is grounded in a growing body of research linking inflammatory processes to depression, and in the observation that lung cancer and its treatments can themselves drive systemic inflammation. The investigators are careful to note that more research is needed before any conclusions can be drawn about this potential mechanism. Nevertheless, the inclusion of inflammatory measures reflects a broader trend in psychedelic science, which increasingly seeks to understand not only the subjective psychological effects of compounds like psilocybin but also their possible interactions with the body’s physiological systems. Any such effect, if confirmed in future work, could be particularly relevant for cancer patients, in whom inflammation, mood and disease progression are closely intertwined.

For one study participant, Betty Paschall, the therapy marked a turning point after a devastating diagnosis. Paschall was diagnosed with stage 4 lung cancer and initially found herself overwhelmed by depression despite receiving treatment for her cancer. She described her state at that time in stark terms, saying she did not want to live and felt like she was the walking dead. After participating in the study, Paschall reported meaningful changes in her outlook and daily life. She began engaging again in activities she had abandoned and found herself reconnecting with the people and experiences that had once brought her joy. Her family noticed the difference as well. She said her sister and daughter both saw a change in her, and that she started to get back to herself a little more. Her account, while a single participant’s experience rather than a scientific result, illustrates the kind of transformation the trial is designed to measure systematically.

Despite the optimism surrounding the study, the researchers are emphatic that psilocybin-assisted therapy remains experimental and is not appropriate for every patient. Participants undergo careful screening before enrollment, a process intended to identify individuals for whom a psychedelic intervention might pose risks, and treatment is provided only under close medical supervision. The controlled conditions of the trial, including the presence of trained therapists and the clinical setting, are integral to both safety and the therapeutic model being tested. The investigators stress that the study’s purpose is to generate rigorous evidence, not to promote unsupervised use of psychedelic substances, and that any future clinical application would depend on the results of this and subsequent trials.

If the study succeeds, the investigators say, it could help identify which patients with lung cancer are most likely to benefit from psilocybin-assisted therapy and lay the groundwork for larger studies aimed at expanding treatment options for cancer-related depression. Wagener observed that cancer care has made major advances, but that treatment for the depression, anxiety and distress that can come with advanced cancer has not moved as quickly. He expressed the hope that this research will help the care team better support the whole person, not just the cancer. That framing captures the trial’s central ambition: to bring the same rigor and innovation to the psychological suffering of lung cancer patients that has transformed their medical treatment, and in doing so to close a gap that has persisted even as survival rates have improved. Patients interested in being screened to participate in the study can contact the research team at Ohio State for more information about eligibility and enrollment.

Subject of Research: Psilocybin-assisted therapy as a treatment for depression in advanced lung cancer patients

Article Title: Clinical trial tests psilocybin-assisted therapy for depression in advanced lung cancer patients

Article References: Clinical trial tests psilocybin-assisted therapy for depression in advanced lung cancer patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: psilocybin, lung cancer, depression, clinical trial, psychedelic-assisted therapy, mental health, Ohio State University, OSUCCC – James, existential distress, cancer care, inflammation, psychotherapy